Keith Goldan

Track

Insider profile

Currently holds a position at OptiNose Inc

Performance

Overall performance
2.0
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -5% 8.2% 15.1%
Success rate 40% 68% 82%
Transactions
12 8% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return -23%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Chief Financial Officer OptiNose Inc Jan. 1, 2017 -
Chief Financial Officer Fibrocell Science Inc Nov. 4, 2016 - Jan. 1, 2017
Chief Financial Officer, Principal Accounting Officer Fibrocell Science Inc June 1, 2015 - Nov. 4, 2016
Chief Financial Officer, Senior Vice President, Treasurer, Corporate Secretary Fibrocell Science Inc March 18, 2015 - June 1, 2015
Keith Goldan's trades of Syndax Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-02 2026-06-01
S Sale
25,052 -35.6%
379.95
US$28,874 		25,052 -35.6% 379.95 US$28,874
2026-06-01 2026-06-01
PrS Proposed sale
68,997
293.74
US$3,490,773 		68,997 293.74 US$3,490,773
2026-02-10 2026-02-09
S Sale
40,434 -32.9%
377.07
US$2,641,299 		40,434 -32.9% 377.07 US$2,641,299
2026-02-09 2026-02-09
PrS Proposed sale
3,410
21.03
US$71,707 		3,410 21.03 US$71,707
2026-02-06 2026-02-06
S Sale
2,082 -1.4%
20.62
US$42,931 		2,082 -1.4% 20.62 US$42,931
2026-02-06 2026-02-06
PrS Proposed sale
2,082
20.62
US$42,931 		2,082 20.62 US$42,931
2025-07-18 2025-07-16
S Sale
1,296 -1.4%
9.29
US$12,033 		1,296 -1.4% 9.29 US$12,033
2025-07-16 2025-07-16
PrS Proposed sale
1,296
9.29
US$12,034 		1,296 9.29 US$12,034
2025-02-12 2025-02-10
S Sale
3,777 -4.0%
15.50
US$58,559 		3,777 -4.0% 15.50 US$58,559
2025-02-10 2025-02-10
PrS Proposed sale
3,777
15.50
US$58,559 		3,777 15.50 US$58,559
2024-06-17 2024-06-14
B Purchase
1,250 +2.4%
20.03
US$25,037 		1,250 +2.4% 20.03 US$25,037
2023-06-14 2023-06-13
S Sale
577 -18.0%
22.31
US$12,873 		577 -18.0% 22.31 US$12,873
2022-03-17 2022-03-16
US OptiNose Inc (OPTN)
S Sale
4,617 -3.2%
2.11
US$9,742 		4,617 -3.2% 2.11 US$9,742
2021-12-17 2021-12-16
US OptiNose Inc (OPTN)
S Sale
580 -0.6%
1.64
US$951 		580 -0.6% 1.64 US$951
2021-09-17 2021-09-16
US OptiNose Inc (OPTN)
S Sale
578 -0.6%
2.79
US$1,612 		578 -0.6% 2.79 US$1,612
2021-06-17 2021-06-17
US OptiNose Inc (OPTN)
S Sale
576 -0.6%
3.73
US$2,148 		576 -0.6% 3.73 US$2,148
2021-03-17 2021-03-15
US OptiNose Inc (OPTN)
S Sale
2,304 -2.5%
3.92
US$9,032 		2,304 -2.5% 3.92 US$9,032
2020-09-23 2020-09-23
US OptiNose Inc (OPTN)
PP Planned purchase
2,500 +34.5%
3.90
US$9,742 		2,500 +34.5% 3.90 US$9,742